Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting
June 1, 2021
BEIJING and BOSTON, June 1, 2021 /PRNewswire/ — Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th. The first trial (poster #2580; NCT04481009) is designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of YH003 (an anti-CD40 monoclonal antibody (mAb)) […]
Biocytogen Best Research Paper Award commends typhoid toxin and potential peptide therapy research
May 27, 2021
Boston, May 27, 2021, adapted from Cornell Chronicle, Graduate students and postdoctoral researchers in the Department of Microbiology and Immunology from Cornell University faced stiff competition for this year’s Biocytogen Best Research Paper Award. Their work in infectious disease and host immune responses has been recognized in peer-reviewed journals, and faculty members faced the difficult […]
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1
March 23, 2021
BOSTON and BEIJING, March 22, 2021 /PRNewswire/ — Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences’ anti-PD-1 monoclonal antibody, Toripalimab Injection (TUOYI®), has demonstrated encouraging anti-tumor activity in a dose-escalation Phase I clinical trial in Australia. The study was designed to evaluate the safety, tolerability, pharmacokinetics, […]
Biocytogen announces acquisition of a third Beacon Optofluidic system
March 5, 2021
BOSTON, Feb. 25, 2021 /PRNewswire/ — Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen’s antibody discovery service platform in the greater Boston area for collaborations across the globe.Founded on its successful gene editing platform, Biocytogen […]
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab
February 10, 2021
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ — Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences’ anti-PD-1 antibody Toripalimab (TUOYI®), demonstrated encouraging anti-tumor activity in an ongoing Phase I/II clinical trial in Australia. The trial is a multicenter, open label study, with an initial multiple-dose-escalation […]
Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement
February 1, 2021
Beijing, China and Tokyo, Japan, February 1st, 2021 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and LiberoThera Co.,Ltd (“LiberoThera”) announced today that they have entered into an agreement for strategic collaboration on fully human therapeutic GPCR antibody development incorporating Biocytogen’s world-class antibody discovery expertise based on its fully human antibody RenMab™ mouse platform with LiberoThera’s state-of-the-art […]
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China
January 29, 2021
BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ — Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001) in patients with solid tumors. In May 2020, Eucure Biopharma initiated a first-in-human Phase I dose-escalation trial of YH001 in advanced solid […]
Beijing Biocytogen Company Name Change Annuncement
January 15, 2021
Effective December 29th, 2020, our parent company name has officially changed from Beijing Biocytogen Co., Ltd. to Biocytogen Pharmaceuticals (Beijing) Co., Ltd. There is no change in company ownership, operations, or pre-existing contractual agreements. Please feel free to contact us at [email protected] if you have any inquiries. We thank you for your continued support.
Biocytogen Enters into RenMab™/RenLite™ Licensing Agreement with Xencor
December 7, 2020
Xencor to use RenLite™ Fully Human Antibody Mouse Platform to discover novel antibody drugs WAKEFIELD, Mass. and BEIJING, Dec. 7, 2020 /PRNewswire/–Beijing Biocytogen Co., Ltd. , Biocytogen Boston Corp (collectively as “Biocytogen”) announced today that they have reached an agreement with Xencor, Inc., for the licensing of Biocytogen’s fully human antibody RenMab™/RenLite™ Mouse platform to enhance Xencor’s monoclonal […]
Biocytogen Teams With Ina Research To Boost Presence In Japan
December 4, 2020
Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with Ina Research Co., Ltd. (hereinafter “INA”) to expand its business in Japan market. As one of the world’s largest pharmaceutical markets, Japan has an established reputation for innovative drug research […]
